WA-LSBIO
22.12.2020 10:02:17 CET | Business Wire | Press release
LSBio (LSBio™), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolute Antibody, Ltd. and its sister company Kerafast. Terms of the transaction were not disclosed.
LSBio provides IHC-validated reagent antibodies and services to the global community of academic, pharmaceutical and biotech researchers. The Company has built a catalog of more than 750,000 reagent antibodies, assay kits, proteins, and biochemicals, and its acquisition of Absolute Antibody and Kerafast further expands its product portfolio by adding a range of unique reagents and antibody services.
Absolute Antibody specializes in recombinant antibody technology, offering antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies and Fc Fusion proteins, engineered into new and useful formats. In 2018, Absolute Antibody merged with Kerafast Inc., a Boston-based company that facilitates access to unique laboratory-made reagents, to further the availability of recombinant antibodies. The new acquisition combines a strong recombinant antibody portfolio with LSBio’s expertise in application-specific validation to make sequence-defined, reproducible antibodies more widely available for IHC and other key research applications.
“We are very excited to add Absolute Antibody and Kerafast into the LSBio family of companies,” said Dr. Heather Holemon, CEO of LSBio. “It provides an opportunity to offer more to our customers by adding their recombinant antibody production and engineering capabilities as well as their highly complementary product portfolio. This transaction aligns with our goal of providing researchers access to what they are asking for as far as superior consistency and better validation.”
“We are delighted to be joining forces with the LSBio team,” said Dr. Nicholas Hutchings, founder and CEO of Absolute Antibody. “Absolute Antibody was founded with a vision to make engineered recombinant antibodies accessible to all, and we have grown rapidly as the demand for recombinant antibody technology has increased. That vision remains and working with LSBio enables us to continue growing both the recombinant antibody catalog and our custom services, while still delivering the highest level of product quality and customer satisfaction.”
The acquisition marks the latest investment by LSBio to rapidly build its product portfolio. In 2019, LSBio acquired both Nordic-MUbio and Everest Biotech to strengthen the Company’s offering of proprietary monoclonal and polyclonal antibodies. All LSBio companies currently retain their independent names, websites and employees, with the entire family of companies owned by St. Louis-based private equity firm Thompson Street Capital Partners.
Absolute Antibody, Ltd. were advised by Pivotal Scientific Limited, a specialist Mergers and Acquisitions business based in Oxford, UK & Clark Holt, a specialist law firm based in Swindon UK.
About LSBio
LSBio (www.lsbio.com ) enables researchers by providing a variety of antibodies and research reagents. Previous acquisitions of Nordic-MUbio and Everest Biotech have strengthened the company’s offering of proprietary monoclonal and polyclonal antibodies. The continued emphasis for LSBio has been on building the portfolio and coupling that with application-specific antibody validation. Through ongoing in-house testing, over 15,000 of the LSBio antibodies have been identified as exceptional IHC reagents and given the IHC-plus™ brand. LSBio itself was acquired by Thompson Street Capital Partners (TSCP) in 2018.
About Absolute Antibody
Absolute Antibody (www.absoluteantibody.com ) was founded in 2012, with the vision to make engineered recombinant antibodies available to all. The company offers antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of engineered recombinant antibodies. Absolute Antibody customers include leading pharmaceutical, biotechnology and diagnostics companies, as well as academic researchers in more than 60 different countries worldwide.
About Kerafast
Kerafast, Inc. (www.kerafast.com ) is a reagent company whose primary mission is to make unique laboratory-made research tools easily accessible to the global scientific community. Since its founding in 2011, Kerafast has partnered with more than 190 academic research institutions internationally and provided reagents to scientists in 63 countries across six continents. In 2018, Kerafast merged with Absolute Antibody, a company specializing in recombinant antibody technology, to further improve the selection of research tools available to the scientific community.
About TSCP
Thompson Street Capital Partners is a St. Louis-based private equity firm focused on investing in founder-led middle market businesses. TSCP has acquired more than 150 companies in the Healthcare & Life Science Services, Software & Technology Services and Business Services & Engineered Products sectors and have managed more than $2.6 billion since being founded in 2000. TSCP partners with management teams to increase value by accelerating growth, both organically and via complementary acquisitions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201222005100/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release
Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP
Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch23.4.2026 10:00:00 CEST | Press release
Now with new international vehicle, Pantheon offers clients global evergreen access to full suite of private equity, private credit secondaries, and infrastructure secondaries Pantheon bolsters its globally recognized, specialist approach in infrastructure secondaries in the evergreen market with the launch of the Pantheon Global Infrastructure Secondaries Fund (“PGIS”) PGIS will tap the expertise of Pantheon’s $26.9 billion1 institutional infrastructure franchise Fund marks latest in Pantheon’s growing, $15 billion2 global evergreen platform, which now includes semi-liquid evergreen offerings across private equity, private credit secondaries and infrastructure secondaries in the US and internationally3 Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the exp
KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents23.4.2026 09:02:00 CEST | Press release
Providing a high-availability compute foundation for seamless AI agent deployment, greater resource efficiency, and enterprise-grade reliability. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use. Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At presen
Samsung Epis Holdings Reports First Quarter 2026 Financial Results23.4.2026 08:54:00 CEST | Press release
Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KR
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency23.4.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy. Widespread net sales growth of 25.5% year-on-year at constant currency1,aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%). Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion. Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom